Locus-specific HERV expression identifies an aggressive, NK-depleted, checkpoint-refractory acral melanoma phenotype - Report - MDSpire

Locus-specific HERV expression identifies an aggressive, NK-depleted, checkpoint-refractory acral melanoma phenotype

  • By

  • Jez L. Marston

  • Tongyi Fei

  • Helena Reyes-Gopar

  • Matthew L. Bendall

  • Douglas F. Nixon

  • July 6, 2026

  • 0 min

Share

Identification of Aggressive Acral Melanoma Phenotype with Depleted NK Cells

Overview

This study identifies a three-locus HERV signature that stratifies acral melanoma (AM) tumors by overall survival and highlights the association of high-risk tumors with depleted NK cells and resistance to immune checkpoint inhibitors.

Background

Acral melanoma (AM) is a subtype of melanoma that arises on non-sun-exposed skin and is associated with poorer survival outcomes compared to UV-driven melanomas. AM exhibits unique molecular characteristics, including a low mutation burden and an immunosuppressive tumor microenvironment, which contribute to its resistance to standard therapies.

Data Highlights

FindingValue
HERV signature C-index0.778 (95% CI: 0.614–0.914)
Kaplan–Meier log-rank p-value0.003
HR for high-risk tumors2.19 (95% CI: 1.38–3.47, p = 0.001)
NK-cell depletion correlationρ = −0.58 (FDR p = 0.004)
Odds ratio for ICI response0.20 (p = 0.075)

Key Findings

  • A three-locus HERV signature stratifies AM tumors by overall survival.
  • High-risk tumors are associated with depleted NK cells.
  • High-risk tumors show elevated LIN28A and HMGA2 expression.
  • High-risk tumors have reduced odds of responding to immune checkpoint inhibitors.
  • A structurally intact HERV-K antigen candidate was identified for further evaluation.

Clinical Implications

Understanding the immune landscape of high-risk AM tumors could inform future research directions.

Conclusion

This research highlights the distinct molecular characteristics of acral melanoma.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. The ASCO Post, 2018 -- Activity of T Cells in Metastatic Melanoma Resistant to Immune Checkpoint Inhibitor Treatment
  3. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, ScienceDirect
  4. The ASCO Post — Activity of T Cells in Metastatic Melanoma Resistant to Immune Checkpoint Inhibitor Treatment
  5. Blood Cancer Journal — DEK Modulates Proliferative Ability of B-cells and Correlates with Aggressive Characteristics in Low-Grade B-cell Lymphomas
  6. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
  7. Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian
  8. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - ScienceDirect

Original Source(s)

Related Content